Amidst a complex and rapidly changing regulatory scheme, McMillan’s cannabis industry lawyers are at the leading edge of industry developments. McMillan’s Cannabis Practice Group is one of the largest groups of its kind in Canada. Our specialized team of lawyers works closely with a wide range of industry participants, including licensed producers and retailers. They also work with innovators, investors, technology and other service providers, to help them succeed in the medical cannabis industry.
Among Canada’s top business law firms, McMillan is leading the way in providing innovative and practical solutions to business clients in the evolving cannabis industry. Experts in facilitating business growth, McMillan represented Aurora Cannabis Inc. in its US $2.5 billion (CAD $3.2 billion) acquisition of MedReleaf Corp, the largest M&A deal in the Cannabis sector to date in all of Canada. We also represented iAnthus Capital Holdings Inc. in its $835 million acquisition of MPX Bioceutical Corporation, the first public company-to-public company acquisition involving US cannabis assets.
Our lawyers are experienced professionals with significant in-depth knowledge of the laws, regulations and business landscape of Canada’s medical cannabis industry. Our cannabis industry lawyers provide clients with valuable legal solutions for financing, accessing public markets, licensing and regulation, employment law and workplace issues, mergers and acquisitions, tax structuring and intellectual property matters, whether you are just entering the market or you are already established in the sector.
We help our clients lead by:
- structuring financing arrangements through private equity, public markets, and venture capital,
- navigating the complex medical marijuana regulatory system, assisting with regulatory approvals,
- advising on mergers, acquisitions and divestitures,
- assisting with labelling, advertising and distribution matters,
- drafting comprehensive employment agreements and workplace policies in compliance with applicable laws,
- advising on tax matters, and
- assisting with patents, trademarks, licensing, outsourcing and strategic alliances
Insights (10 Posts)View More
On January 11, 2024, CIRO proposed amendments aimed at strengthening short selling regulations in Canada.
On November 16, 2023, the CSA and CIRO published CSA/CIRO Staff Notice 23-332 Summary of Comments and Responses to CSA/IIROC Staff Notice 23-329.
The Competition Bureau's submission to support Health Canada's legislative review of the Cannabis Act investigates the competitive dynamics of cannabis industry
A recent decision by the Ontario Court of Appeal provides more guidance on good faith.
We look at the recent market analysis of the Canadian cannabis industry and challenges in cannabis restructuring.
Securities regulators provided guidance regarding disclosure of financial interests and conflicts of interest in Cannabis transactions
The Supreme Court of Newfoundland and Labrador (“Supreme Court”) has issued an important decision about the limits of accommodating the use of medically prescribed cannabis by an employee working in a safety-sensitive position.
On June 14, 2019, Health Canada unveiled its Final Regulations for New Cannabis Products
Regulation of CBD in the United States – Balancing Public Safety and Social Considerations with Industry Expectations and Consumer Demand
CBD (cannabidiol) is currently an industry hot topic.
Whether you are new to the cannabis industry, interested in starting a cannabis business, or have been seizing opportunities for a while — join us for an interactive day on the strategic and legal implications of the legalization of cannabis in Canada.
Get updates delivered right to your inbox. You can unsubscribe at any time.